HR 6888
117th Congress
House
Health
Helping Experts Accelerate Rare Treatments Act of 2022
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 2, 2022
Referred to the Subcommittee on Health.
Mar 1, 2022
Referred to the House Committee on Energy and Commerce.
Mar 1, 2022
Introduced in House
Plain-English summary
Helping Experts Accelerate Rare Treatments Act of 2022
This bill requires studies on processes for approving drugs that treat rare diseases and conditions.
The Government Accountability Office (GAO) must contract with an appropriate entity to study the European Union's process for evaluating the safety and efficacy of such drugs, including any flexibilities or mechanisms that are specific to rare diseases or conditions. The GAO must also conduct a study about the Food and Drug Administration's mechanisms for ensuring that patient and physician perspectives are considered when evaluating and approving drugs for rare diseases or conditions.
The GAO must report to Congress the results of these studies.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2